Today Concert Pharmaceuticals released the first of two phase 3 clinical trials for the unmet medical need Alopecia Areata. The results were impressive and mirrored their phase 2 clinical trial. The phase 3 had 41.5% of patients in the 12 mg group achieving the SALT 20 or lower score after 24 weeks of treatment. Note that the lower the SALT score the more head of hair that has grown back. The percentage of the 8 mg group of patients achieving a SALT score of 20 or less was 29%. Adverse events were reported inline with their phase 2 clinical trial. Below are results from three companies targeting Alopecia with their respective drugs.
Concert's CTP-543 (green bars in graph) is the most effective in the high dose of 12mg and their lower dose of 8mg versus the others, high and low dose. The second phase 3 THRIVE AA2 will read out in the third quarter. Thank you for reading.
No comments:
Post a Comment